Mylan CEO claims to be frustrated in wake of EpiPen price controversy

Nicholas Leider | | Health Exec | Management

EpiPens have been in the news lately—and not for the right reasons. The 400 percent increase in price over the last decade for the medication for allergic reactions has drawn criticism from the highest places. An article in Forbes takes Mylan, the company that produces the EpiPen, to task, directing specific questions to CEO Heather Bresch for her reaction to the controversy.

"When it comes to people and healthcare, pharmaceutical companies should take note of these recent debacles," writes Emily WIllingham in Forbes. "Perhaps it’s time to realize that for them, it’s not just about doing good business. Because their business is human health, it’s also about being a good business."

Check out the full article by clicking the link below:

No One Is More Frustrated About EpiPen Pricing than Mylan's CEO, Says Mylan's C…

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.